These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33686114)

  • 1. Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells.
    Buzzetti M; Morlando S; Solomos D; Mehmood A; Cox AWI; Chiesa M; D'Alessandra Y; Garofalo M; Topham CH; Di Leva G
    Sci Rep; 2021 Mar; 11(1):5374. PubMed ID: 33686114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Anti Leukemia Effect of a Novel Hsp90 and a Pan Cyclin Dependent Kinase Inhibitors.
    Abdalla AN; Abdallah ME; Aslam A; Bader A; Vassallo A; Tommasi N; Malki WH; Gouda AM; Mukhtar MH; El-Readi MZ; Alkahtani HM; Abdel-Aziz AA; El-Azab AS
    Molecules; 2020 May; 25(9):. PubMed ID: 32397330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Tumor and Chemosensitizing Effects of the CDK Inhibitor Dinaciclib on Cholangiocarcinoma
    Sungwan P; Kidoikhammouan S; Thonsri U; Saengboonmee C; Wongkham S; Okada S; Seubwai W
    In Vivo; 2024; 38(5):2284-2293. PubMed ID: 39187317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.
    Saqub H; Proetsch-Gugerbauer H; Bezrookove V; Nosrati M; Vaquero EM; de Semir D; Ice RJ; McAllister S; Soroceanu L; Kashani-Sabet M; Osorio R; Dar AA
    Sci Rep; 2020 Oct; 10(1):18489. PubMed ID: 33116269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.
    Rajput S; Khera N; Guo Z; Hoog J; Li S; Ma CX
    Oncotarget; 2016 Aug; 7(35):56864-56875. PubMed ID: 27486754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of dinaciclib and CAN508 hybrids as CDK inhibitors.
    Odeh DM; Allam HA; Baselious F; Mahmoud WR; Odeh MM; Ibrahim HS; Abdel-Aziz HA; Mohammed ER
    Drug Dev Res; 2024 May; 85(3):e22193. PubMed ID: 38685605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.
    Feldmann G; Mishra A; Bisht S; Karikari C; Garrido-Laguna I; Rasheed Z; Ottenhof NA; Dadon T; Alvarez H; Fendrich V; Rajeshkumar NV; Matsui W; Brossart P; Hidalgo M; Bannerji R; Maitra A; Nelkin BD
    Cancer Biol Ther; 2011 Oct; 12(7):598-609. PubMed ID: 21768779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
    Valenciaga A; Saji M; Yu L; Zhang X; Bumrah C; Yilmaz AS; Knippler CM; Miles W; Giordano TJ; Cote GJ; Ringel MD
    JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.
    Danilov AV; Hu S; Orr B; Godek K; Mustachio LM; Sekula D; Liu X; Kawakami M; Johnson FM; Compton DA; Freemantle SJ; Dmitrovsky E
    Mol Cancer Ther; 2016 Nov; 15(11):2758-2766. PubMed ID: 27550941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors.
    Floros KV; Jacob S; Kurupi R; Fairchild CK; Hu B; Puchalapalli M; E Koblinski J; Dozmorov MG; Boikos SA; Scaltriti M; Faber AC
    Cell Death Dis; 2021 Feb; 12(2):179. PubMed ID: 33589591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational Combination Therapy for Melanoma with Dinaciclib by Targeting BAK-Dependent Cell Death.
    Xu X; Eshima S; Kato S; Fisher DE; Sakurai H; Hayakawa Y; Yokoyama S
    Mol Cancer Ther; 2020 Feb; 19(2):627-636. PubMed ID: 31744894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective but not pan-CDK inhibition abrogates 5-FU-driven tissue factor upregulation in colon cancer.
    Kayser A; Wolff A; Berlin P; Duehring L; Henze L; Mundkowski R; Bergmann W; Müller-Hilke B; Wagner C; Huehns M; Oehmcke-Hecht S; Maletzki C
    Sci Rep; 2024 May; 14(1):10582. PubMed ID: 38719932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl-xL silenced cells.
    Premkumar DR; Jane EP; Thambireddy S; Sutera PA; Cavaleri JM; Pollack IF
    Mol Carcinog; 2018 Apr; 57(4):469-482. PubMed ID: 29240261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis.
    Bates DJ; Salerni BL; Lowrey CH; Eastman A
    Cancer Biol Ther; 2011 Aug; 12(4):314-25. PubMed ID: 21768777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK9 Inhibition by Dinaciclib Is a Therapeutic Vulnerability in Epithelioid Hemangioendothelioma.
    Pobbati AV; Burtscher A; Rajaram Siva N; Hallett A; Romigh T; Che K; Zhao B; Coker JA; Wang N; Stauffer SR; Rubin BP
    Clin Cancer Res; 2024 Sep; 30(18):4179-4189. PubMed ID: 39052240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.
    Lin SF; Lin JD; Hsueh C; Chou TC; Wong RJ
    PLoS One; 2017; 12(2):e0172315. PubMed ID: 28207834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.
    Cihalova D; Ceckova M; Kucera R; Klimes J; Staud F
    Biochem Pharmacol; 2015 Dec; 98(3):465-72. PubMed ID: 26300056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK9 inhibition as an effective therapy for small cell lung cancer.
    Valdez Capuccino L; Kleitke T; Szokol B; Svajda L; Martin F; Bonechi F; Krekó M; Azami S; Montinaro A; Wang Y; Nikolov V; Kaiser L; Bonasera D; Saggau J; Scholz T; Schmitt A; Beleggia F; Reinhardt HC; George J; Liccardi G; Walczak H; Tóvári J; Brägelmann J; Montero J; Sos ML; Őrfi L; Peltzer N
    Cell Death Dis; 2024 May; 15(5):345. PubMed ID: 38769311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with
    Nelson LJ; Castro KE; Xu B; Li J; Dinh NB; Thompson JM; Woytash J; Kipp KR; Razorenova OV
    Cell Cycle; 2022 May; 21(10):1103-1119. PubMed ID: 35240916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the CDK inhibitor dinaciclib in vitro and in vivo in T-cell acute lymphoblastic leukemia.
    Moharram SA; Shah K; Khanum F; Marhäll A; Gazi M; Kazi JU
    Cancer Lett; 2017 Oct; 405():73-78. PubMed ID: 28756008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.